Business
WuXi Biologics Reports Record 2025 Annual Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development and manufacturing, today announced audited results for the year ended December 31, 2025 ("Reporting Period").
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps)","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; adjusted EBITDA grew 22.8% YoY and adjusted net profit increased 22.0% YoY","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share increased 48.8%; adjusted earnings per share grew 19.7%","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Free cash flow reached RMB 2.3 billion, increasing over 70% YoY","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Record-high 209 new integrated projects signed, including 6 late-stage programs; 2/3 of new signings in bispecifics and ADCs","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Total number of integrated projects reached 945, one of the largest portfolios of complex biologics","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"156 INDs filed in 2025; capacity expanded to 200 INDs and 20 BLAs/MAAs annually","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed 28 PPQs (+75% YoY), while 34 PPQs scheduled for 2026","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Total backlog increased to US$23.7 billion; backlog within 3 years increased to US$4.5 billion","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Leveraging integrated R-D-M capabilities, bi- & multi-specifics have established as a core growth engine, delivering 120%+ YoY revenue growth","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"Industry-leading targeted integration cell line platform launched, achieving 8+ g/L titer with 30 clones screened and IND-ready in 6 months","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"CRDMO capabilities continued to strengthen across geographies","length":61,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1298,"olType":false},{"type":"text","content":"HONG KONG, March 24, 2026 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock ...